Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share (HOWL)

CUSIP: 95075A107

Q3 2022 13F Holders as of 30 Sep 2022

Holder snapshot 6 signals
Share change
+1,885,141
SEC-reported price per share
$4.51
Indexed holders
39
Value change
+$8,517,407
Number of buys
16
Number of sells
15
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
48,566,310

Security key

95075A107

Report period

Q3 2022

Indexed institutions

39

Top holders

10

Ownership snapshot

Top reported holders of HOWL - Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
0/15
Latest evidence
30 Jun 2022
13F Highest disclosed value: $17,554,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. has the largest disclosed position value at $17.55M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Disclosed position value Top 5
RA CAPITAL MANAGEMENT, L.P. $17.55M
MPM ASSET MANAGEMENT LLC $17.52M
MPM BioImpact LLC $9.77M
PFM Health Sciences, LP $7.08M
ADAGE CAPITAL PARTNERS GP, L.L.C. $4.09M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$17,554,000
4,291,881 shares
— 30 Jun 2022
MPM ASSET MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$17,522,000
4,284,172 shares
— 30 Jun 2022
MPM BioImpact LLC
13F
Company
13F
—
denominator unverified
$9,767,000
2,388,011 shares
— 30 Jun 2022
PFM Health Sciences, LP
13F
Company
13F
—
denominator unverified
$7,079,000
1,730,723 shares
— 30 Jun 2022
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
13F
—
denominator unverified
$4,092,000
1,000,597 shares
— 30 Jun 2022
DEERFIELD MANAGEMENT COMPANY, L.P.
13F
Company
13F
—
denominator unverified
$3,919,000
958,125 shares
— 30 Jun 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
39
Shares
20,956,559
Indexed holders
39
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2022 vs Q2 2022 Across Filers

Q2 2022 indexed holders
39
Q3 2022 indexed holders
39
Indexed holder difference
0
Investor Q2 2022 Shares Q3 2022 Shares Share Diff Share Chg % Q2 2022 value Q3 2022 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .